Indian Biosimilar Makers See Potential Earlier U.S. Entry In Budget Plan
This article was originally published in PharmAsia News
Executive Summary
Indian makers of generic biotech drugs see the U.S. budget proposal as potentially easing the way onto the American pharmaceutical market for Indian products